Search research articles
Contact Us
Filters
Showing results (101-110 of 113) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2007
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
Malik E Juweid, Sigrid Stroobants, Otto S Hoekstra, et al.
Leukemia & Lymphoma
|
October 21, 2014
(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study
Karen Juul Mylam, Lale Kostakoglu, Martin Hutchings, et al.
Blood
|
April 2, 2020
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial
Heiko Schöder, Mei-Yin C Polley, Michael V Knopp, et al.
European Radiology
|
January 6, 2026
Evaluating indeterminate bone lesions and lymph nodes on PSMA-PET: a multidisciplinary consensus algorithm and 1-year implementation results
Sungmin Woo, Angela Tong, Anton S Becker, et al.
Leukemia & Lymphoma
|
November 12, 2025
Early assessment of treatment response in AML using FLT PET/cT: a trial of the ECOG-ACRIN Cancer Research Group (EAI141)
Robert Jeraj, Fenghai Duan, Ryan J Mattison, et al.
Haematologica
|
March 25, 2014
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale
Andrea Gallamini, Sally F Barrington, Alberto Biggi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2021
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
Grzegorz S Nowakowski, Fangxin Hong, David W Scott, et al.
Blood Advances
|
August 31, 2022
A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma
Catherine Thieblemont, Loic Chartier, Ulrich Dührsen, et al.
Blood
|
February 9, 2026
A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma
Catherine Diefenbach, Opeyemi Jegede, Victoria Wang, et al.
Blood
|
May 31, 2024
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL
Mitchell R Smith, Opeyemi A Jegede, Peter Martin, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 113) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2007
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
Malik E Juweid, Sigrid Stroobants, Otto S Hoekstra, et al.
Leukemia & Lymphoma
|
October 21, 2014
(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study
Karen Juul Mylam, Lale Kostakoglu, Martin Hutchings, et al.
Blood
|
April 2, 2020
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial
Heiko Schöder, Mei-Yin C Polley, Michael V Knopp, et al.
European Radiology
|
January 6, 2026
Evaluating indeterminate bone lesions and lymph nodes on PSMA-PET: a multidisciplinary consensus algorithm and 1-year implementation results
Sungmin Woo, Angela Tong, Anton S Becker, et al.
Leukemia & Lymphoma
|
November 12, 2025
Early assessment of treatment response in AML using FLT PET/cT: a trial of the ECOG-ACRIN Cancer Research Group (EAI141)
Robert Jeraj, Fenghai Duan, Ryan J Mattison, et al.
Haematologica
|
March 25, 2014
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale
Andrea Gallamini, Sally F Barrington, Alberto Biggi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2021
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
Grzegorz S Nowakowski, Fangxin Hong, David W Scott, et al.
Blood Advances
|
August 31, 2022
A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma
Catherine Thieblemont, Loic Chartier, Ulrich Dührsen, et al.
Blood
|
February 9, 2026
A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma
Catherine Diefenbach, Opeyemi Jegede, Victoria Wang, et al.
Blood
|
May 31, 2024
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL
Mitchell R Smith, Opeyemi A Jegede, Peter Martin, et al.
Page
of 12